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Platinum-based anticancer drugs cause neurotoxicity. In particular, oxaliplatin produces early-develop-
ing, painful, and cold-exacerbated paresthesias. However, the mechanism underlying these bothersome
and dose-limiting adverse effects is unknown. We hypothesized that the transient receptor potential
ankyrin 1 (TRPA1), a cation channel activated by oxidative stress and cold temperature, contributes to
mechanical and cold hypersensitivity caused by oxaliplatin and cisplatin. Oxaliplatin and cisplatin
evoked glutathione-sensitive relaxation, mediated by TRPA1 stimulation and the release of calcitonin
gene-related peptide from sensory nerve terminals in isolated guinea pig pulmonary arteries. No calcium
response was observed in cultured mouse dorsal root ganglion neurons or in naïve Chinese hamster ovary
(CHO) cells exposed to oxaliplatin or cisplatin. However, oxaliplatin, and with lower potency, cisplatin,
evoked a glutathione-sensitive calcium response in CHO cells expressing mouse TRPA1. One single
administration of oxaliplatin produced mechanical and cold hyperalgesia in rats, an effect selectively aba-
ted by the TRPA1 antagonist HC-030031. Oxaliplatin administration caused mechanical and cold allo-
dynia in mice. Both responses were absent in TRPA1-deficient mice. Administration of cisplatin evoked
mechanical allodynia, an effect that was reduced in TRPA1-deficient mice. TRPA1 is therefore required
for oxaliplatin-evoked mechanical and cold hypersensitivity, and contributes to cisplatin-evoked
mechanical allodynia. Channel activation is most likely caused by glutathione-sensitive molecules,
including reactive oxygen species and their byproducts, which are generated after tissue exposure to
platinum-based drugs from cells surrounding nociceptive nerve terminals.
 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Platinum-based drugs are commonly used for the treatment of
various types of cancers. Unfortunately, their clinical benefit is
challenged by severe adverse effects to the nervous, auditory,
hematologic, and renal systems [34]. The third-generation plati-
num drug oxaliplatin [4] shows a dramatic reduction in renal tox-
icity and ototoxicity, but exhibits a unique neurotoxic profile [30].
In addition to a chronic sensory neuropathy typical of otherfor the Study of Pain. Published by
of Preclinical and Clinical
aly. Tel.: +39 055 427 1329;platinum-based drugs [30], oxaliplatin causes an acute syndrome,
described as cold-exacerbated paresthesia of the hands, feet, peri-
oral region, and throat, which affects almost all patients, and devel-
ops rapidly, persisting for several days [47]. Neurotoxicity by
platinum-based drugs, and not tumor progression, is often the
cause of treatment discontinuation, dose reduction, or hospitaliza-
tion [39].
Because attempts to mitigate platinum-based drugs’ neurotox-
icity with neuroprotective strategies have yielded unsatisfactory
results, a more precise understanding of the mechanism(s) respon-
sible for the neurotoxic action of platinum-based drugs is required.
Ion channels, and particularly voltage sensitive sodium channels,
have been proposed as contributors to the neurotoxic action of
platinum-based drugs [46,38]. More recently, attention has been
paid to the transient receptor potential (TRP) family of ionElsevier B.V. All rights reserved.
1622 R. Nassini et al. / PAIN

152 (2011) 1621–1631channels. In rodents, deletion of the TRP vanilloid 1 (TRPV1) chan-
nel (which is expressed by the largest subset of nociceptive neu-
rons) worsened cisplatin-induced symptoms [9]. In contrast,
TRPV1 seems to contribute to the heat-induced hyperalgesia in cis-
platin-treated animals [43], whereas acid-sensing ion channels 3
(ASIC3), and the adenosine triphosphate gated P2X3 channel, seem
to contribute to mechanical hyperalgesia [20], and the TRP melast-
atin 8 (TRPM8) to oxaliplatin-evoked cold allodynia [17].
At least part of the cytotoxic effect of oxaliplatin is mediated by
its ability to generate reactive oxygen species (ROS) [26,32], and
cisplatin-evoked damage of mouse cochleae is associated with
the generation of lipid peroxidation byproducts, including 4-
hydroxynonenal [29]. In addition, it has recently been reported
that oxaliplatin-induced mechanical hyperalgesia, and heat- and
cold-evoked allodynia in rats, is attenuated by antioxidants,
including acetyl-L-carnitine, a-lipoic acid, or vitamin C, suggesting
that oxidative stress contributes to these painful conditions [22].
The TRP ankyrin 1 (TRPA1), a calcium-permeable cation channel
co-expressedwith TRPV1 in a subpopulation of nociceptive primary
sensory neurons [41,21,37], is activated by pungent ingredients
present in an array of spices, including allyl isothiocyanate (mus-
tard, wasabi), cinnamaldehyde (cinnamon), and others [21,37]. Ro-
bust evidence has been accumulated indicating that ROS [2,8,40]
and various endogenous byproducts deriving from ROS induced
peroxidation of plasma membrane phospholipids, including acro-
lein [7] and 4-hydroxynonenal [45] gate TRPA1, thereby causing
pain and neurogenic inflammation. It has been reported [41] and
more recently confirmed [24] that TRPA1 is activated by noxious
cold temperatures. Thus, because TRPA1 is a sensor of both oxida-
tive stress [8] and cold temperatures [24], we have hypothesized
that TRPA1 mediates mechanical and cold hypersensitivity pro-
voked by platinum-based anticancer drugs. Our data show that in
rat and mouse models, TRPA1 is a main contributor of mechanical
and cold hyperalgesia/allodynia induced by oxaliplatin or cisplatin,
thus shedding light on the mechanisms underlying painful sensory
neuropathy associated with the use of these drugs.2. Materials and methods
2.1. Reagents
If not otherwise indicated, all reagents were from Sigma–Al-
drich (Milan, Italy). HC-030031 was synthesized as previously de-
scribed [3]. Olcegepant was kindly donated by Dr. H. Doods
(Boehringer-Ingelheim, Inselheim, Germany).
2.2. Animals
All animal experiments were carried out in accordance with the
European Union Community Council guidelines and approved by
the local ethics committee. Dunkin-Hartley guinea pigs (male,
250 g) (Charles River, Milan, Italy), Sprague–Dawley rats (male,
250 g), C57BL/6 mice (male, 25 g) (Harlan Laboratories, Milan,
Italy), wild-type (Trpa1+/+) or TRPA1-deficient mice (Trpa1/),
generated by heterozygous mice on a C57BL/6 background [7],
were used. Behavioral experiments were done in a quiet, tempera-
ture-controlled room (20C to 22C) between 10 am and 4 pm and
were performed with an operator blinded to the genotype and the
status of drug treatment. Animals were killed with a high dose of
intraperitoneal (i.p.) sodium pentobarbital (200 mg/kg).
2.3. Organ bath studies
Pulmonary arteries were excised from guinea pigs and sus-
pended at a resting tension of 1 g in 10-mL organ baths, and theassay was performed as previously described [33]. The tissues
were bathed in aerated (95% O2 and 5% CO2) Krebs–Henseleit solu-
tion containing (in mM): 119 NaCl, 25 NaHCO3, 1.2 KH2PO4, 1.5
MgSO4, 2.5 CaCl2, 4.7 KCl, and 11 D-glucose, maintained at 37C,
which contained the neutral endopeptidase inhibitor thiorphan
(10 lM) and the muscarinic antagonist atropine (10 lM). After
45 minutes of equilibration, tissues were contracted twice with
phenylephrine (1 lM), with a 45-minute washing out period
between the first and second administration. Once the contractile
response to the second administration of phenylephrine had
reached a plateau, oxaliplatin (100 lM), cisplatin (100 lM), mus-
tard oil (MO, 10 lM) or their respective vehicles (0.1%, 0.1%, and
0.01%, dimethyl sulfoxide [DMSO]) and capsaicin (1 lM) or its
vehicle (0.01% ethanol) were added and left in contact with the
preparation for the entire duration of the experiment. In some
experiments, tissues were pretreated with the TRPA1 blocker,
HC-030031 (10 lM), the calcitonin gene-related peptide (CGRP)
receptor antagonist, olcegepant (BIBN4096BS, 10 lM), the TRPV1
blocker, capsazepine (CPZ; 10 lM), or their respective vehicles
(0.1% DMSO for HC and BIBN4096B, 0.1% ethanol for CPZ). In addi-
tion, some tissues were pretreated with glutathione (GSH, 1 mM)
or its vehicle (isotonic saline), 1 hour prior to the second adminis-
tration of phenylephrine. Some tissue preparations were desensi-
tized to capsaicin (10 lM for 20 minutes) as previously reported
[3]. Motor activity of tissue preparation was recorded isometrically
on a force transducer (Harvard Apparatus, Ltd, Kent, United King-
dom). The results were expressed as percentage of relaxation of
the maximum contractile response induced by phenylephrine.
2.4. Cell culture and isolation of primary sensory neurons
A tetracycline-regulated system for inducible expression of
TRPA1 in Chinese hamster ovary (CHO) cells transfected with the
cDNA of the mouse TRPA1 (mTRPA1-CHO) was used, as described
previously [41]. Naïve CHO cells were used as controls. The pri-
mary cell culture of sensory neurons has been described previously
for trigeminal ganglia, and was slightly modified for dorsal root
ganglia (DRG) neurons [24]. Lumbosacral (L5-S2) DRGs were bilat-
erally excised under a dissection microscope. The ganglia were
washed in phosphate-buffered saline solution (PBS, Invitrogen,
Carlsbad, California, USA) and collected in ice-cold Leibowitz med-
ium (L15, Invitrogen). The ganglia were then transferred into warm
(37C) Dulbecco modified essential medium (DMEM) containing
0.025% collagenase (type IA) and incubated (95% air, 5% CO2) at
37C. After 45 minutes, tissue was gently triturated with a fire-pol-
ished glass pipette, and the resultant suspension was centrifuged
at 1700 rpm for 10 minutes. The pellet was resuspended in
DMEM/F-12 (1:1) containing Glutamax (Invitrogen) supplemented
with 10% fetal calf serum (Invitrogen) and 100 lg/mL penicillin/
streptomycin (Invitrogen). Cells were plated on poly-L-lysine-
coated glass coverslips and used after 1 day in culture. In some
experiments, isolated DRG neurons were co-cultured with naïve
CHO cells. DRG neurons were plated on poly-L-lysine-coated glass
coverslips and 1 hour afterward, naïve CHO cells have been plated
in the same coverslips. Co-cultures were maintained with the same
medium used for DRG neurons and used 1 day afterward.
2.5. Calcium imaging experiments
Cells were incubated with 2 lM Fura-2AM ester for 30 minutes
at 37C. Intracellular calcium ([Ca2+]i) concentration was measured
on an Olympus (Tokyo, Japan) CellM system. Fluorescence was
measured during excitation at 340 and 380 nm, and after correc-
tion for the individual background fluorescence signals, the ratio
of the fluorescence at both excitation wavelengths (F340/F380) was
monitored. Experiments were performed using the standard Krebs
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glucose, 10 HEPES and titrated to pH 7.4 with 1 N NaOH. Cells were
exposed to oxaliplatin and cisplatin, (both, 10 to 300 lM), MO
(100 lM), and platinum dichloro diaminocyclohexane (300 lM)
or their respective vehicles (0.3%, 0.1%, and 0.3% DMSO) in the
presence of GSH (1 mM) or its vehicle (isotonic saline). To identify
neurons in DRG neuron cultures, we applied a Krebs-based solu-
tion in which the KCl concentration was increased to 50 mM by
iso-osmotic substitution of NaCl.
2.6. Detection of oxaliplatin-GSH adducts by high-performance liquid
chromatography–electrospray mass spectrometry (HPLC/ESI-MS)
Oxaliplatin (100 lM) and GSH (1 mM) were incubated in equiv-
olumetric amounts in a water medium at 37C. Samples were ta-
ken at time 0 (preincubation) and after 10 minutes of incubation
and analyzed by means of HPLC/ESI-MS. HPLC separations were
performed at 25C using a Hypersil PFP column (150  2.1 mm,
particle size 3 lm) with a linear gradient. The mobile phase was
MeOH/H2O/HCOOH (0.1% v/v) and the gradient program was 10%
to 45% v/v MeOH in 14 minutes. The flow rate was 50 lL/min,
and the injection volume was 10 lL. All measurements were re-
peated twice. ESI source parameters (positive polarity) were: spray
voltage 4 kV, capillary temperature 400C, capillary voltage 18 V,
tube lens 110 V, skimmer offset 0 V. The parallel estimation of
the variation of intensities of chromatographic peaks correspond-
ing to GSH and oxaliplatin absorption, expressed as percentage
areas, was performed by HPLC analysis following previously re-
ported conditions (C18 reverse-phase column eluted with a
CH3CN/H2O gradient containing 0.1% of the ion pairing agent, mon-
itored at 220 nm) [16].
2.7. Superoxide anion production assay
Naïve CHO cells were grown in 6-well plates until 90% to 100%
confluence, and starved in serum-free DMEM overnight before
treatment. Similarly, cells (including neuronal and nonneuronal
cells) isolated from rat DRG ganglia were plated on poly-L-lysine-
coated 6-well plates at a density equivalent of 20 ganglia per well,
obtaining a 70% to 80% confluence. Cells were then incubated
either with oxaliplatin or cisplatin, both 300 lM, or their vehicle
(0.3% DMSO), in serum-free DMEM containing cytochrome C
(1 mg/mL) for 2 hours at 37C, in the presence or absence of bovine
superoxide dismutase (SOD) (300 U/mL). The supernatants were
collected, and the optical density was spectrophotometrically mea-
sured at 550 nm. The superoxide anion amount was calculated by
using an extinction coefficient of 2.1  104/M/cm and expressed as
nmol/mg protein/2 hours.
2.8. Oxaliplatin and cisplatin-induced painful neuropathy models
After habituation and baseline measurements of pain sensitiv-
ity, animals were randomized into treatment groups. Rats were
treated with a single intravenous (i.v.) administration of oxalipl-
atin (2 mg/kg) or its vehicle (isotonic saline) [23]. C57BL/6,
Trpa1+/+, or Trpa1/ mice were treated with a single i.p. admin-
istration of oxaliplatin (3 mg/kg) or its vehicle (isotonic saline)
[17]. In another set of experiments, C57BL/6 or Trpa1+/+ and
Trpa1/ mice were treated with repeated doses of cisplatin
(2 mg/kg, i.p.) or its vehicle (isotonic saline) three times per week
over 5 weeks (cumulative dose of 30 mg/kg) [9]. Starting the
third week of treatment with cisplatin, the animals began to lose
weight, whereas no weight loss was observed after oxaliplatin
treatment. Oxaliplatin and cisplatin were dissolved in isotonic
saline, and the volume was adjusted to 1 mL/kg for i.v. and
10 mL/kg for i.p. administration.2.8.1. Randall-Selitto paw-withdrawal test
Oxaliplatin-induced mechanical hyperalgesia was assessed by
measuring the paw-withdrawal thresholds in rats using an Ugo Ba-
sile analgesimeter (Ugo Basile, Varese, Italy). Briefly, rats were al-
lowed into individual Plexiglas cages and acclimatized for 10 to
15 minutes, after which the hind paws were exposed to the test
stimulus. The paw-withdrawal threshold was determined before
(basal level threshold) and after drug administration. The effect
of oxaliplatin was tested for 20 days, starting immediately after
drug administration, which was counted as day 1. Intragastric
(i.g.) HC-030031 (100 mg/kg) or its vehicle (0.5% carboxymethyl-
cellulose) and capsazepine (4 mg/kg, i.p.) or its vehicle (5%, DMSO)
were administered at day 2 and 15 after oxaliplatin or vehicle
administration. In another experimental setting, rats were treated
with an intraplantar injection of capsaicin (20 lg/50 lL/paw) or its
vehicle (1% ethanol) and the paw-withdrawal threshold was deter-
mined 30 minutes after drug administration [19]. Capsazepine
(4 mg/kg, i.p.) or its vehicle (5% DMSO) were administered 10 min-
utes before capsaicin or vehicle administration. Nociceptive
thresholds were determined at 5-minute intervals, and the mean
of three readings was defined as the nociceptive threshold. Cutoff
pressure was 200 g. Data are expressed as the pressure threshold
(g) required to elicit the paw withdrawal.
2.8.2. Von Frey hair test
Oxaliplatin and cisplatin-induced mechanical allodynia was
measured in C57/BL6, Trpa1+/+ or Trpa1/ mice by using the up-
and-down paradigm [10]. Mechanical nociceptive threshold was
determined before (basal level threshold) and after drug adminis-
tration. The effect of oxaliplatin was tested for 30 days, starting
immediately after drug administration, which was counted as
day 1. The effect of cisplatin was tested at 5 weeks after the end
of the treatment cycle. Data are expressed as the mean threshold
values (g).
2.8.3. Cold stimulation
Cold hyperalgesia induced by oxaliplatin was assessed in rats by
using the tail immersion test in a water bath maintained at 10C,
with a cutoff time of 15 seconds. The time taken by the rat to with-
draw its tail from the cold water was the nociceptive measure.
Three measurements were taken at 5-minute intervals, and were
averaged. The baseline of the latency was determined before (basal
level) and after drug administration [23]. The effect of oxaliplatin
was tested for 8 days, starting immediately after drug administra-
tion, which was counted as day 1. HC-030031 (100 mg/kg, i.g.) or
its vehicle (0.5% carboxymethylcellulose) was administered at
day 2 after the administration of oxaliplatin or its vehicle.
Cold allodynia was assessed in mice by measuring the acute
nocifensive responses to the acetone-evoked evaporative cooling
as previously described [17]. Briefly, the animal was held by the
hand and a droplet (50 lL) of acetone, formed on the flat-tip needle
of a syringe, was gently touched to the plantar surface of the hind
paw. The mouse was immediately put in a cage with a transparent
floor, and the time spent in elevation and licking of the plantar re-
gion over a 60-second period was measured. Acetone was applied
3 times at a 10- to 15-minute intervals, and the average of eleva-
tion/licking time was calculated. Cold allodynia was measured in
mice before (baseline) and for 30 days after drug treatment.
2.9. Real-time polymerase chain reaction (PCR)
For real-time PCR studies, DRGs were isolated frommice treated
with oxaliplatin (3 mg/kg, i.p.) or its vehicle before or at different
times (6 and 24 hours and 3, 10, and 30 days) after oxaliplatin
treatment. Total RNA was isolated from tissues using a tissue
homogenizer (ULTRA-TURAX IKA T10 basic, IKA, Staufen,
1624 R. Nassini et al. / PAIN

152 (2011) 1621–1631Germany) and TRIzol Reagent (Invitrogen), according to the manu-
facturer’s instructions. Samples were treated with the RNase-free
DNase I (Applied Biosystems, Carlsbad, California, USA) and quan-
tified on a Picodrop spectrophotometer (Picodrop Limited, United
Kingdom). Reverse transcription of 500 ng total RNA was carried
out using SuperScript III Platinum Two-Step qRT-PCR Kit (Invitro-
gen) according to the manufacturer’s directions. Two sets of pri-
mer-probes were designed using the Primer Express Software
version 3.0 (Applied Biosystems). The chosen reporter fluorophores
for TaqManMGB probes were VIC for the 28S rRNA internal control
and 6-carboxyfluorescein (FAM) for the TRPA1 gene. The 2 sets of
primer-probes were as follows: set 1, 28SRNA-FW (forward) 50-CC
GCTAAGGAGTGTGTAACAACTC-30, 28SRNA-RE (reverse) 50-CTCCA
GCGCCATCCATTT-30, 28SRNA probe 50-VIC-CCGAATCAACTAGCCC
TG-30; and set 2, TRPA1-FW (forward) 50-CAGGATGCTACGGTTT
TTTCATTACT-30, TRPA1-RE (reverse) 50-GCATGTGTCAATGTTTGGT
ACTTCT-30 and TRPA1 probe 50-FAM-TCTTAATATGCAAGAAACA
CG-30. The chosen primers and probes were subjected to Basic
Local Alignment Search Tool BLAST database searches to find any
sequence similarities. Real-time quantitative PCR was performed
using StepOnePlus Real-Time PCR System (Applied Biosystems).
All samples were run in triplicate in a final volume of 25 lL con-
taining 12.5 lL of 2 TaqMan Gene Expression PCR Master Mix,
300 nM of each primer, 250 nM of each probe, and 4 lL of RT reac-
tion, according to the manufacturer’s instructions (Applied Biosys-
tems). Amplification conditions were: 50C for 2 minutes and 95C
for 10 minutes, followed by 40 cycles of 95C for 30 seconds and
60C for 1 minute. The fold change of TRPA1 mRNA levels was cal-
culated relative to the 28S rRNA internal control, using the 2DDCT
comparative method.2.10. Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were
performed by the unpaired 2-tailed Student t test for comparisons
between two groups, the one-way analysis of variance followed by
the post hoc Bonferroni test for comparisons of multiple groups,
and the chi-square test for comparing two proportions. Values of
P < 0.05 were considered statistically significant.3. Results
3.1. Oxaliplatin and cisplatin activate TRPA1 on nociceptive nerve
terminals via a glutathione-sensitive mechanism in the guinea pig
pulmonary artery
To test the hypothesis that oxaliplatin and cisplatin may acti-
vate TRPA1 on sensory nerve terminals, we utilized the isolated
guinea pig pulmonary artery assay [33]. In keeping with previous
findings [33], the neurogenic relaxation evoked by capsaicin was
markedly reduced by pre-exposure of the tissue to an elevated
concentration of capsaicin, which renders sensory nerve terminals
unresponsive to any stimulus [42]. The CGRP receptor antagonist,
olcegepant [13], and the TRPV1 antagonist, capsazepine, but not
the TRPA1 selective antagonist, HC-030031 [35], blocked the effect
of capsaicin (Fig. 1A and C). The selective TRPA1 agonist, MO,
caused relaxation that was inhibited by capsaicin-desensitization,
olcegepant, and HC-030031, but not by capsazepine (Fig. 1B), thus
suggesting that MO evokes CGRP-mediated relaxation via stimula-
tion of TRPA1-expressing sensory nerve terminals (Fig. 1B). Finally,
exposure of guinea pig pulmonary arteries to oxaliplatin (100 lM)
or cisplatin (100 lM) caused relaxation that was capsaicin-sensi-
tive and inhibited by olcegepant and HC-030031, but unaffected
by capsazepine (Fig. 1C to E). We also found that the ROS and
the reactive aldehyde scavenger GSH [1,15] left relaxation evokedby capsaicin or MO unchanged (Fig. 1A and B), but markedly inhib-
ited responses to oxaliplatin and cisplatin (Fig. 1D and E). Thus, in
this bioassay platinum-based drugs activate the TRPA1 channel,
expressed on capsaicin-sensitive nociceptive nerve terminals,
through a GSH-sensitive mechanism.
3.2. Oxaliplatin and cisplatin activate TRPA1 by an indirect mechanism
mediated by oxidative stress and release superoxide anion
To test the hypothesis whether platinum drugs directly activate
TRPA1, we studied the calcium response to oxaliplatin and cis-
platin in cultured mouse DRG neurons, which express TRPA1,
and in CHO cells transfected with the cDNA of the mouse TRPA1
(mTRPA1-CHO). Neither oxaliplatin nor cisplatin (both 300 lM)
caused any calcium response in mouse DRG neurons (Fig. 2A). In
contrast, oxaliplatin evoked a calcium response in mTRPA1-CHO
cells (Fig. 2B and D). The number of responding cells increased
with the oxaliplatin concentration (10 to 300 lM) (Fig. 2D). The ef-
fect of oxaliplatin (300 lM) was almost entirely abated in the pres-
ence of GSH (Fig. 2B and D). Cisplatin was a weaker agonist than
oxaliplatin, causing a calcium response in a significant number
(approximately 40%) of mTRPA1-CHO cells only at the 300 lM con-
centration (Fig. 2C and D). The response to cisplatin was also aba-
ted by GSH (Fig. 2C and D). Neither oxaliplatin nor cisplatin evoked
any response in untransfected cells (Fig. 2B and C). We also inves-
tigated the effect of oxaliplatin or cisplatin in co-cultures of DRG
neurons, obtained fromwild-type mice, and naïve CHO cells. Under
these conditions, both oxaliplatin (300 lM) and cisplatin (300 lM)
caused a calcium response in a small but significant proportion of
cells, which also responded to MO. Cells responding to oxaliplatin
were 13% (n = 16) of the total number of cells responding to MO
(n = 123). Cells responding to cisplatin were 11% (n = 11) of the to-
tal number of cells responding to MO (n = 98). The effect induced
by both oxaliplatin and cisplatin was 39% ± 7% and 33% ± 7% of that
induced by MO, respectively. In the presence of GSH (1 mM) of 70
cells responding to MO, none responded to oxaliplatin. Similarly,
no response to oxaliplatin was seen in co-cultures with neurons ta-
ken from TRPA1-deficient mice (as expected, under these circum-
stances, no response to MO was reported). Similar results were
obtained with cisplatin. In the presence of GSH, no response to cis-
platin was observed in the cells that responded to MO (n = 87). No
response to cisplatin or MO was detected in co-cultures with neu-
rons taken from TRPA1-deficient mice.
Next we investigated the mechanism by which GSH blocked the
oxaliplatin effect. To this purpose, oxaliplatin (100 lM) and GSH
(1 mM) were incubated for a period of time (10 minutes) that ex-
ceeded the amount of time required to fully evoke the calcium re-
sponse by oxaliplatin in mTRPA1-CHO cells. As reported previously
[16], prolonged incubation periods (hours) with GSH may reduce
the concentration of the intact oxaliplatin. However, HPLC/ESI-
MS analysis showed that 10 minutes of incubation with GSH was
not sufficient to reduce oxaliplatin concentration (Supplementary
Fig. 1). This indicates that inhibition of oxaliplatin-evoked calcium
response was not due to a direct inactivation of the chemothera-
peutic agent by GSH. Therefore, we propose that platinum-based
drugs do not directly activate TRPA1, but rather channel stimula-
tion occurs indirectly via the generation of reactive GSH-sensitive
chemical species. The potentially reactive oxaliplatin metabolite,
platinum dichloro diaminocyclohexane (300 lM), failed to evoke
any calcium response in mTRPA1-CHO (Supplementary Fig. 2).
The level of superoxide anion in the supernatant of naïve CHO
cells after exposure to oxaliplatin (300 lM) (6.89 ± 0.93 nmol/mg
protein/2 hours, n = 6) was significantly higher (P < 0.02) than the
level measured after exposure to the vehicle (4.02 ± 0.59 nmol/
mg protein/2 hours, n = 8). Similarly, cisplatin (300 lM) increased
superoxide anion level (5.95 ± 0.49 nmol/mg protein/2 hours,
Fig. 1. Oxaliplatin and cisplatin gate TRPA1 channel and induce neurogenic relaxation in guinea pig pulmonary artery via a glutathione (GSH)-dependent mechanism. (A and
C) Capsaicin (5: CPS; 1 lM) relaxes guinea pig isolated pulmonary artery precontracted with phenylephrine (d: PE; 1 lM) via CGRP release from sensory nerves. (A) The
relaxation evoked by CPS is abolished by capsaicin desensitization (CPS-des; 20 lM for 20 minutes), by pretreatment with the CGRP receptor antagonist, olcegepant
(BIBN4096BS; 10 lM), and the TRPV1 antagonist, capsazepine (CPZ; 10 lM), but was unaffected by the TRPA1 selective antagonist, HC-030031 (HC; 10 lM) and GSH (1 mM).
(B) The selective TRPA1 agonist, mustard oil (MO; 10 lM), evokes a similar neurogenic relaxation that is abated by CPS-des, BIBN4096BS, and HC, but is unaffected by CPZ or
GSH pretreatment. (C) Representative traces and (D) pooled data of the vasorelaxant effect induced by oxaliplatin (.: OXA; 100 lM) and (E) cisplatin (CIS; 100 lM) in
precontracted pulmonary artery. Relaxation is abated by CPS-des, BIBN4096BS, and HC, but not by CPZ. Pretreatment with GSH completely prevents relaxation induced by
OXA and CIS. Veh is the combination of vehicles of the various antagonists. Values are mean ± SEM of nP 4 experiments. ⁄P < 0.05 vs. Veh; one-way ANOVA and Bonferroni
test.
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the vehicle (4.02 ± 0.61 nmol/mg protein/2 hour, n = 5). In the
supernatant of cultured DRG cells, superoxide anion levels were
under the sensitivity of the method after exposure to either oxa-
liplatin and cisplatin or their vehicles (data not shown).
3.3. Oxaliplatin-evoked mechanical and cold hyperalgesia in rats are
mediated by TRPA1
Next we investigated whether TRPA1 could be involved in mod-
els of mechanical and cold hypersensitivity in rats and mice. Inagreement with data reported earlier [23], we found that i.v.
administration of oxaliplatin (2 mg/kg) produced an early and
remarkable reduction in mechanical paw-withdrawal threshold
in rats. The reduction (approximately 60% from baseline), already
visible at day 1, remained constant until day 8, then declined pro-
gressively to plateau again around day 15 (Fig. 3A). In another set
of experiments, the administration of the TRPA1 selective antago-
nist HC-030031 (100 mg/kg, i.g.) [35] 2 days (Fig. 3B) or 15 days
(Fig. 3C) after oxaliplatin administration produced a time-depen-
dent and complete reversal of the mechanical hyperalgesia evoked
by oxaliplatin. The effect of HC-030031, in keeping with previous
Fig. 2. Oxaliplatin and cisplatin activate TRPA1 by an indirect mechanism mediated by a glutathione (GSH)-sensitive mechanism. (A) Oxaliplatin (OXA; 100 to 300 lM) and
cisplatin (CIS; 100 to 300 lM) do not evoke any intracellular calcium ([Ca2+]i) response in mouse dorsal root ganglion (DRG) neurons (identified by the response to 50 mM K+),
which respond to mustard oil (MO; 100 lM) (representative traces and pooled data). Approximately 40% of the cells respond to MO (dark cyan), whereas the remaining are
insensitive to MO (black). (B and C) Representative traces and (D) pooled data of [Ca2+]i responses evoked by OXA (10 to 300 lM) and CIS (10 to 300 lM) in CHO cells stably
transfected with mouse TRPA1 cDNA. MO (100 lM) is used as positive control. Neither OXA or CIS (both 300 lM) evoke any calcium response in untransfected CHO cells. (D)
The effect of OXA and CIS (both 300 lM) is entirely abated by glutathione (GSH; 1 mM). Lines represent average signal of all recorded cells with standard error indicated by
dotted lines (A to C). Pooled data represent the comparison of the percentage of cells responding to OXA, OXA plus GSH, CIS, CIS plus GSH, or MOwith the total amount of cells
analysed. Numbers indicate responding cells/total cells analysed (A and D). ⁄P < 0.05 vs. OXA or CIS (both 300 lM); chi-square test.
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60 minutes after dosing (Fig. 3B and C). HC-030031 did not affect
mechanical paw-withdrawal threshold in naïve animals (Fig. 3Band C). Finally, pretreatment with capsazepine, at a dose (4 mg/
kg, i.p.) that completely reverted mechanical hyperalgesia evoked
by the intraplantar injection of capsaicin (20 lg/50 lL/paw)
Fig. 3. Oxaliplatin induces mechanical hyperalgesia via TRPA1 activation in rats. A single dose of oxaliplatin (OXA; 2 mg/kg, i.v.) produces a time-dependent reduction in the
mechanical paw-withdrawal threshold (A). At days (d) 2 (B) and 15 (C), the treatment with HC-030031 (HC; 100 mg/kg, i.g) completely reverses the mechanical hyperalgesia
60 minutes after dosing. Treatment with capsazepine (CPZ; 4 mg/kg, i.p.), which completely reverses mechanical hyperalgesia induced by capsaicin (CPS; 20 lg/50 lL/paw)
(F), does not affect mechanical hyperalgesia induced by OXA either at day 2 (D) or day 15 (E) after treatment. Veh is the vehicle of OXA. Values are mean ± SEM of n = 8–10
rats. #P < 0.05 vs. Veh OXA in A; Student t test; ⁄P < 0.05 vs. Veh OXA-Veh HC and Veh OXA-HC in B and C or Veh OXA-Veh CPZ and Veh OXA-CPZ in D and E or Veh CPZ-Veh
CPS in F; §P < 0.05 vs. OXA-Veh HC in B and C; one-way ANOVA and Bonferroni test. BL, baseline withdrawal threshold.
R. Nassini et al. / PAIN

152 (2011) 1621–1631 1627(Fig. 3F), did not affect mechanical hyperalgesia induced either 2
(Fig. 3D) or 15 (Fig. 3E) days after oxaliplatin administration. Thus,
the present data propose a major role for TRPA1 in oxaliplatin-
evoked mechanical hyperalgesia in rats, whereas they rule out
any contribution by TRPV1.
Following the same protocol of administration [23], we investi-
gated whether oxaliplatin produced thermal (cold) hyperalgesia
measured by the immersion of the tail in a cold (10C) water bath.
Indeed, a marked and significant reduction in tail withdrawal la-
tency was observed at days 2 and 3 from oxaliplatin administration
(Fig. 4A). This effect of oxaliplatin was reverted by HC-030031,
60 minutes after dosing, with a kinetic similar to the inhibition
of mechanical hyperalgesia (Fig. 4B). HC-030031 did not affect cold
sensitivity in naïve animals (Fig. 4B). Therefore, present pharmaco-
logical evidence supports a major role for TRPA1 in oxaliplatin-
evoked cold hyperalgesia in rats.
3.4. Oxaliplatin-evoked mechanical allodynia and cold hypersensitivity
in mice are mediated by TRPA1 activation
The administration of a single dose of oxaliplatin (3 mg/kg, i.p.)
produced, as reported previously [18], an early-developing reduc-
tion in mechanical nociceptive threshold assayed by the Von Frey
hair test in C57BL/6 mice. The reduction from baseline value was
significant already at day 3 and persisted until day 15 to 20 after
drug administration (Fig. 5A). The same experimental paradigm
was applied to Trpa1+/+ or Trpa1/ mice. Oxaliplatin treatment
produced mechanical allodynia in Trpa1+/+ mice (Fig. 5C), with a
time course similar to that observed in C57BL/6 mice. The allodynic
effect of oxaliplatin was completely absent in Trpa1/ mice
(Fig. 5C). It should be noted that the response to oxaliplatin in
Trpa1/ mice was superimposable to the responses observed in
both Trpa1/ and Trpa1+/+ mice treated with the oxaliplatin vehi-
cle (Fig. 5C).As shown elsewhere [17], C57BL/6 mice injected with a single
dose of oxaliplatin (3 mg/kg, i.p.) showed early developing cold
hypersensitivity, which was assayed by the time spent licking
the hind paw after acetone application for cooling stimulation.
The increase in cold sensitivity peaked at day 3 and returned to
baseline 15 days after oxaliplatin administration (Fig. 5B). A similar
response was observed in Trpa1+/+ mice, whereas no cold hyper-
sensitivity was seen in Trpa1/ mice (Fig. 5D). As shown for
mechanical allodynia, responses to cold stimulus after the vehicle
of oxaliplatin were similar in Trpa1/ and Trpa1+/+ mice, and nei-
ther were different from those produced by oxaliplatin in Trpa1/
mice (Fig. 5D). Capsazepine, administered at a dosage (30 mg/kg,
i.p.) that was previously reported to inhibit TRPM8 [48], did not
produce any significant reduction in cold allodynia in mice (Sup-
plementary Fig. 3).
As previously reported [9], 5 weeks after repeated (3 times per
week for 5 weeks) administration of cisplatin (2 mg/kg, i.p.) C57BL/
6 mice developed mechanical allodynia (Fig. 5E). Following the
same experimental protocol, we found that mechanical allodynia,
evoked by cisplatin in Trpa1+/+, was significantly reduced in
Trpa1/mice (Fig. 5F). Genetic findings indicate that TRPA1 is nec-
essary and sufficient to produce mechanical and cold allodynia
after oxaliplatin administration in mice, and that TRPA1 also con-
tributes markedly to cisplatin mechanical allodynia.
3.5. Messenger RNA TRPA1 expression
Finally, we evaluated the expression of the messenger RNA of
TRPA1 (TRPA1 mRNA) in mouse DRG after 1 single in vivo admin-
istration of oxaliplatin (3 mg/kg, i.p.). mRNA TRPA1 was moder-
ately and significantly increased only 6 hours after oxaliplatin
treatment, but no increase was observed after 6 hours. Thus, oxa-
liplatin only transiently and moderately increases mRNA TRPA1
expression in DRG neurons (Fig. 6).
Fig. 4. Oxaliplatin induces cold allodynia via TRPA1 activation in rats. A single dose of oxaliplatin (OXA; 2 mg/kg, i.v.) produces a time-dependent reduction in the tail
withdrawal latency to cold (10C) (A). At day (d) 2, treatment with HC-030031 (HC; 100 mg/kg i.g) completely reverses the cold (B) allodynia for 60 minutes after dosing. Veh
is the vehicle of OXA. Values are mean ± SEM of n = 8 to 10 rats. #P < 0.05 vs. Veh OXA in A; Student t test; ⁄P < 0.05 vs. Veh OXA-Veh HC and Veh OXA-HC in B; §P < 0.05 vs.
OXA-Veh HC in B; one-way ANOVA and Bonferroni test. BL, baseline withdrawal threshold.
Fig. 5. Oxaliplatin induces mechanical allodynia and cold hypersensitivity via TRPA1 activation in mice. The administration of a single dose of oxaliplatin (OXA; 3 mg/kg, i.p.)
induces in C57BL/6 mice a time-dependent reduction in mechanical nociceptive threshold (A), and cold allodynia (B) with a maximum effect at days (d) 10 and 3 after OXA
administration, respectively. The development of mechanical (C) and cold (D) allodynia observed in Trpa1+/+ mice after OXA treatment is completely absent in Trpa1/ mice.
(E) Repeated doses of cisplatin (CIS; 2 mg/kg), given 3 times per week throughout 5 weeks, induce a significant reduction in mechanical nociceptive threshold in C57BL/6
mice. (F) The mechanical allodynia evoked by the same treatment in Trpa1+/+ was significantly reduced in Trpa1/ mice. Veh is the vehicle of OXA or CIS. Values are
mean ± SEM of n = 8 to 10 mice. #P < 0.05 vs. Veh OXA and Veh CIS in A and B; Student t test; ⁄P < 0.05 vs. Veh OXA-Trpa1+/+ in C and D or vs. CIS (BL) and CIS-Trpa1+/+ (BL) in E
and F and §P < 0.05 vs. OXA-Trpa1/ in C and D or vs. Veh CIS (week 5) and CIS-Trpa1/ (week 5) in E and F; one-way ANOVA and Bonferroni test. BL, baseline withdrawal
threshold.
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Fig. 6. Effect of oxaliplatin on the expression of TRPA1 mRNA in mouse dorsal root
ganglia (DRG). Mice were given an intraperitoneal injection of oxaliplatin (OXA;
3 mg/kg) or its vehicle (Veh; isotonic saline) and DRG were harvested from mice
before (baseline, time0 group) or at different times (h, hours; d, days) after treatment.
Total RNA was extracted, and relative TRPA1 mRNA amounts were measured by
Taqman real-time polymerase chain reaction (Applied Biosystems, Carlsbad, Cali-
fornia, USA). mRNA TRPA1 levels are expressed as fold change over the time 0 group
after normalizing to 28S RNA. Each bar is themean ± SEM of at least 4 mice. ⁄P < 0.05
vs. Basal group and §P < 0.05 vs. Veh; one-way ANOVA and Bonferroni test.
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Here, we confirm previous observations obtained in both rats
and mice [17,18,23] that a single dose of oxaliplatin produces ra-
pid-onset and time-dependent mechanical and cold hypersensitiv-
ity. Pharmacological evidence obtained by using the TRPA1 and
TRPV1 channel antagonists (HC-030031 and capsazepine, respec-
tively) suggests that TRPA1 is involved in mechanical (during both
the early and the late plateau) and cold hypersensitivity evoked by
oxaliplatin in rats. Further and robust support to the hypothesis
that TRPA1 plays a major role in mechanical and cold allodynia is
derived from genetic data. Indeed, our major finding is represented
by the observation that both mechanical and cold hypersensitivity
evoked by oxaliplatin administration is completely absent in
TRPA1-deficient mice. The contribution of TRPA1 to mechanical
hypersensitivity does not seem confined to oxaliplatin, as TRPA1-
deficient mice also developed a noticeably reduced mechanical
allodynia after cisplatin administration. Thus, TRPA1 appears to
be markedly involved in painful neurotoxicity by platinum-based
drug.
Various mechanisms have been advocated to explain the both-
ersome and dose-limiting painful neuropathy associated with the
use of oxaliplatin [39]. These include altered intracellular signaling
pathways [22], and more recently, altered regulation of the activity
of ionic channels, particularly of voltage-gated sodium channels
[46,38]. A recent article focused on the role of the TRPV1, TRPM8,
ASIC3, and P2X3 receptors on oxaliplatin-induced neuropathy
[20]. The hypothesis that TRPM8 contributes to cold hyperalgesia
evoked by oxaliplatin administration obtained by using an ele-
vated dose of capsazepine [17], which should inhibit TRPM8 [48],
has not been confirmed in our study. In contrast, our findings are
in agreement with the observation that IB4-positive somatosen-
sory neurons play a role in oxaliplatin-induced mechanical and
cold hypersensitivity [22], given that it has recently been reported
that almost half of TRPA1-expressing DRG neurons co-stain with
IB4 [25].
Little information has been collected so far on the role of
TRPA1 in painful neurotoxicity of platinum-based drugs. A recent
investigation has reported a transient increase in TRPA1 mRNA
6 hours after in vitro exposure to oxaliplatin of cultured rat DRG
neurons and 6, 24, and 48 hours, but not 12 hours after exposure
to cisplatin [43]. More importantly, oxaliplatin or cisplatinadministration for 3 weeks to mice in vivo upregulated the TRPA1
mRNA in trigeminal ganglion neurons [43]. However, molecular
biology data were not corroborated by functional experiments.
The study solely tested the role of TRPV1 that was found to be in-
volved in cisplatin-evoked heat, but not mechanical, hyperalgesia
[43]. By using the present experimental protocol, consisting of 1
single injection of oxaliplatin, we also noticed a transient increase
in expression of TRPA1 mRNA in mouse DRG homogenates. How-
ever, the time course of mechanical and cold hypersensitivity (peak
effect was observed at day 10 and day 3, respectively) may hardly
be explained by the transient increase in channel mRNA expres-
sion, which was seen only 6 hours after oxaliplatin administration.
Thus, additional factors must contribute to establishing mechani-
cal and thermal hypersensitivity by oxaliplatin.
Present data have provided evidence to support the contribu-
tion of TRPA1 to the neurotoxic effect of platinum-based drugs.
Although the mechanism(s) through which TRPA1 contributes to
the expression of the hyperalgesic phenotype after exposure to
oxaliplatin and cisplatin remain unknown, the following points
should be considered. Despite some controversies [6], TRPA1 has
been proposed to play a role in cold, mechanical, and chemical
nociception [7,12,24,27,28,41]. However, the role of TRPA1 as a
sensor of electrophilic and reactive compounds, such as those
generated during oxidative stress at sites of tissue injury and
inflammation, has been solidly established [2,44]. Indeed, an
unprecedented series of oxidative stress byproducts has been re-
ported to gate TRPA1, and through this mechanism produce noci-
ceptive responses and neurogenic inflammation. These reactive
agents include H2O2 [40], hypochlorite [8], nitroleic acid [44], acro-
lein [7], 4-hydroxynonenal [45], and other endogenous molecules.
There is evidence that oxaliplatin and cisplatin produce oxidative
stress [26,32] and, more importantly, that the antioxidants,
acetyl-L-carnitine, a-lipoic acid, or vitamin C inhibit oxaliplatin-
induced hyperalgesia in rats [22]. Different oxidative stress
byproducts, via their action on TRPA1, have been reported to reca-
pitulate the ability of oxaliplatin to produce mechanical [5,11,45]
and cold [12] hypersensitivity.
In guinea pig pulmonary arteries, which respond to capsaicin
through the activation of intramural capsaicin-sensitive sensory
nerve terminals and the subsequent release of the vasodilating
peptide CGRP [33], both oxaliplatin and cisplatin evoked vasodila-
tations, which, like that of capsaicin and MO, were mediated by a
neurogenic and CGRP-dependent mechanism. Relaxation evoked
by oxaliplatin or cisplatin was mediated by TRPA1 because it was
selectively inhibited by HC-030031. However, TRPA1-mediated
relaxation evoked by oxaliplatin or cisplatin was, in contrast to
that of MO or capsaicin, abated by GSH, thus suggesting that the
effect of the anticancer drugs on TRPA1 is indirect, and probably
mediated by the generation of oxidative stress byproducts. Further
evidence that oxaliplatin and cisplatin do not directly stimulate
TRPA1 was derived from the observation that both drugs failed
to evoke any calcium response in cultured mouse DRG neurons,
which constitutively express the channel. However, oxaliplatin
and, with lower potency, cisplatin, evoked a GSH-sensitive calcium
response in TRPA1-transfected CHO cells, but not in naïve CHO
cells. Incubation of GSH with oxaliplatin for 10 minutes (a time
period largely exceeding that required to evoke the calcium re-
sponse in CHO cells or to relax isolated pulmonary arteries) did
not affect the concentration of the anticancer drug. This implies
that the scavenging action of GSH is not directed primarily to oxa-
liplatin, but rather to molecules generated after exposure of the tis-
sue/cell to the anticancer drug. Thus, the first requirement for
platinum-based drugs for the promotion of calcium response is
that the target cell must express the TRPA1 channel. An additional
requirement is that either the sensory nerve fiber expressing
TRPA1 or the neighboring cells have the capability to generate
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monary artery tissue and directly in cultured CHO cells that these
two preparations have the capability of producing oxidative stress
byproducts. In contrast, cultured DRG neurons apparently do not
have this capability. In addition, failure of the oxaliplatin metabo-
lite, platinum dichloro diaminocyclohexane [31], to stimulate
TRPA1-expressing CHO cells seems to exclude that electrophilic
metabolites of the anticancer drug contribute to TRPA1-mediated
responses. Experiments performed by co-culturing DRG neurons
and naïve CHO cells support the hypothesis that nonneuronal
neighboring cells, but not sensory neurons per se, generate the
GSH-dependent mechanism responsible for acute activation of
neuronal TRPA1.
Thus, we hypothesize that after in vivo exposure to oxaliplatin
or cisplatin, ROS and/or reactive aldehydes generated by a variety
of nonneuronal cells activate TRPA1 expressed on adjacent sen-
sory nerve terminals, and that this phenomenon contributes to
the expression of the hyperalgesic phenotype. Present experi-
ments cannot, however, exclude completely the hypothesis that
in vivo DRG neuronal and non-neuronal cells have the ability
(lost when they are placed in culture) to produce GSH-sensitive
and TRPA1-activating oxidative stress byproducts. In this case,
somatosensory neurons themselves, through an autocrine- or
paracrine-fashion mechanism, might contribute to TRPA1 activa-
tion. Irrespective of the cell type that generates oxidative stress
byproducts, this series of events seems to occur early after oxa-
liplatin administration, but there is indirect evidence that oxida-
tive stress lasts for days after exposure to oxaliplatin. In fact, the
antioxidants acetyl L-carnitine, a-lipoic acid, and vitamin C,
which profoundly reduced oxaliplatin-evoked mechanical hyper-
algesia, were found to be effective even though they were admin-
istered on the fifth day after oxaliplatin administration [22]. The
mechanism(s) underlying the prolonged increase in TRPA1-med-
iated hyperalgesia caused by oxaliplatin was not investigated in
the present study. However, it has been reported [31] that intra-
cellular or extracellular platinum-bound proteins persist for
50 days after drug administration. We propose that protein mod-
ification induced by oxaliplatin is associated with a durable gen-
eration of oxidative stress byproducts, which in turn are
responsible for TRPA1 activation. Oxaliplatin causes early
mechanical hyperalgesia and cold allodynia, whereas cisplatin
fails to evoke cold allodynia and produces delayed mechanical
hyperalgesia. It is possible that the higher potency or lower doses
of oxaliplatin (with respect to cisplatin) required to produce
GSH-dependent TRPA1 activation (observed in CHO cells and gui-
nea pig pulmonary artery) contribute to the more precocious
occurrence of mechanical hyperalgesia and the generation of cold
allodynia by oxaliplatin. However, it is possible that additional
and hitherto unknown pharmacokinetic/pharmacodynamic prop-
erties of oxaliplatin are responsible for the difference. In conclu-
sion, although present data indicate that TRPA1 contributes to
both oxaliplatin- and cisplatin-evoked neuropathic phenotype,
the precise mechanisms responsible for the specific, and presum-
ably different, involvement of TRPA1 in mechanical and cold
hypersensitivity produced by the two drugs remains to be
identified.
A number of potential neuroprotectants have been challenged
recently to reduce the severe side effects caused by platinum-
based drugs. The most useful prophylactic or curative treatments
seem to be blockers of sodium channels, such as amifostine or car-
bamazepine, and antioxidants such as GSH or a-lipoic acid [36].
However, no evidence-based recommendation can be proposed, gi-
ven that large confirmatory prospective trials are still lacking [36].
The present findings, which reveal the early and primary role of
TRPA1 in oxaliplatin- and cisplatin-evoked mechanical and cold
hypersensitivity, suggest that by tackling this novel mechanism,TRPA1 antagonists may protect patients from neurotoxic effects
without affecting the anticancer potential of platinum-based drugs
and in particular of oxaliplatin.
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